Literature DB >> 25220244

Pregabalin role in inhibition of morphine analgesic tolerance and physical dependency in rats.

Parisa Hasanein1, Saeed Shakeri2.   

Abstract

Pregabalin is recently proposed as analgesic or adjuvant in pain management. While previous preclinical investigations have evaluated pregabalin-opioid interactions, the effect of pregabalin on opioid tolerance and dependency has not yet been studied. Here we evaluated the effects of different doses of pregabalin (50, 100 and 200mg/kg, s.c.) on morphine-induced tolerance and dependency in rats. Adult male Wistar rats were rendered tolerant to analgesic effect of morphine by injection of morphine (10mg/kg, s.c.) twice daily for 7 days. To develop morphine dependence, rats were given escalating doses of morphine. To determine the effect of pregabalin on the development of morphine tolerance and dependence, different doses of pregabalin were administrated before morphine. The tail-flick and naloxone precipitation withdrawal tests were used to evaluate the degree of tolerance and dependence, respectively. Chronic morphine-injected rats showed significant decrements in the percentage maximum possible effect (%MPE) of morphine on the days 5 and 7 (32.5%±3.5, 21.5%±4, respectively) compared to the first day (100%) which showed morphine tolerance. Pregabalin 200mg/kg completely prevented the development of morphine tolerance. In addition, concomitant treatment of morphine with pregabalin attenuated almost all of the naloxone-induced withdrawal signs which include weight loss, jumping, penis licking, teeth chattering, wet dog shakes, rearing, standing, sniffing, face grooming and paw tremor. These data show that pregabaline has a potential anti-tolerant/anti-dependence property against chronic usage of morphine. Therefore, pregabalin appears to be a promising candidate for the treatment of opioid addiction after confirming by future clinical studies.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dependency; Morphine; Pregabalin; Rats; Tolerance

Mesh:

Substances:

Year:  2014        PMID: 25220244     DOI: 10.1016/j.ejphar.2014.08.030

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

Review 1.  Abuse Potential of Pregabalin: A Systematic Review.

Authors:  Ole Schjerning; Mary Rosenzweig; Anton Pottegård; Per Damkier; Jimmi Nielsen
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

2.  Pregabalin Use Among Users of Illicit Drugs: A Cross-Sectional Survey in Southern Germany.

Authors:  Brendan J Snellgrove; Tilman Steinert; Susanne Jaeger
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

Review 3.  Management of Opioid-Tolerant Patients with Acute Pain: Approaching the Challenges.

Authors:  Pamela E Macintyre; Lindy J Roberts; Christine A Huxtable
Journal:  Drugs       Date:  2020-01       Impact factor: 9.546

4.  Prescribed and non-prescribed gabapentin use among persons seeking inpatient opioid detoxification.

Authors:  Michael D Stein; Shannon R Kenney; Bradley J Anderson; Micah T Conti; Genie L Bailey
Journal:  J Subst Abuse Treat       Date:  2019-12-13

Review 5.  Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review.

Authors:  Rainer Freynhagen; Miroslav Backonja; Stephan Schug; Gavin Lyndon; Bruce Parsons; Stephen Watt; Regina Behar
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

6.  Morphine Efficacy, Tolerance, and Hypersensitivity Are Altered After Modulation of SUR1 Subtype KATP Channel Activity in Mice.

Authors:  Cole Fisher; Kayla Johnson; Travis Okerman; Taylor Jurgenson; Austin Nickell; Erin Salo; Madelyn Moore; Alexis Doucette; James Bjork; Amanda H Klein
Journal:  Front Neurosci       Date:  2019-10-22       Impact factor: 4.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.